Stomach Cancer Market Developments and Forecast by 2030

[Research Report] The stomach cancer market size is projected to grow from US$ 3,575.04 million in 2022 to US$ 10,751.42 million by 2030; it is estimated to record a CAGR of 14.8% during 2022–2030.

Market Insights and Analyst View: 

Stomach cancer, also known as gastric cancer, is caused due to the abnormal and out-of-control growth of the malignant cells in the stomach. Risk factors that lead to the risk of stomach cancer include age and food. Indigestion, stomach discomfort, loss of appetite, heartburn, and weight loss are all symptoms of stomach cancer. Different approaches are employed in treating stomach cancers, such as chemotherapy, radiation therapy, and immunotherapy. The stomach cancer market growth is influenced by factors such as the growing incidence of stomach cancer, advancements in treatment, including chemotherapy, surgery, and targeted therapies, and ongoing research and development efforts to improve patient outcomes. With the increasing emphasis on early diagnosis and personalized treatment approaches, the stomach cancer treatment market is expected to continue to expand in the future.

Growth Drivers: 

Businesses in the healthcare market are undertaking various research and development activities to introduce innovative treatments for gastric cancer. Additionally, the treatments are being evaluated in clinical trials, and new approaches are also being constantly developed and investigated through clinical trials. A few of the products in the pipeline are mentioned below:

• In December 2022, Zhejiang Doer Biologics Co., Ltd entered into a clinical trial collaboration agreement with Merck & Co., Inc., to evaluate Doer Bio's anti-Claudin18.2 antibody DR30303, in combination with Merck's anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in patients with gastric or gastroesophageal junction cancer. Under the terms of the agreement, Doer Bio conducted an experimental study based on a mutually- agreed and finalized protocol to investigate the safety and effectiveness of DR30303 in combination with KEYTRUDA in Claudin18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction cancer patients.
• In November 2022, Triumvira Immunologics proclaimed preclinical data for its investigational TAC-T cell therapies CLDN18.2-TAC T and GUCY2C-TAC T, as well as data on HER2-specific TAC-T products. The company showed the updated data on its novel T cell antigen coupler (TAC)-T cell candidate targeting Claudin 18.2 for treating gastric cancer.
• In September 2022, Nuvectis Pharma, Inc. announced positive data for NXP800 in a preclinical xenograft model of ARID1a-mutated gastric carcinoma. Tumor volumes were measured for 28 days after mice in each group were treated with either a vehicle or NXP800 treatment. Tumor regression and significant tumor growth inhibition were the outcomes of NX800 treatment as compared to the control.

Therefore, the increasing number of clinical trials helps raise the availability of gastric cancer treatment worldwide, which, in turn, positively impacts the growth of the stomach cancer market.

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Get FREE CUSTOMIZATION

Stomach Cancer Market: Strategic Insights

• Get Top Key Market Trends of this report.
  This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Free Sample PDF

Report Segmentation and Scope:

The stomach cancer market is segmented on the basis of type, treatment, route of administration, distribution channel, and geography. Based on type, the stomach cancer market is categorized into adenocarcinomas, gastrointestinal stromal tumors, neuroendocrine tumors, lymphoma, and others. Based on treatment, the stomach cancer market is classified into targeted and immunotherapy drugs, chemotherapy and combination drugs, and others. The stomach cancer market, by route of administration, is segmented into oral, parenteral, and others. In terms of distribution channel, the stomach cancer market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Geographically, the stomach cancer market is segmented into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, the UAE, South Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Segmental Analysis:

The stomach cancer market, by type, is categorized into adenocarcinomas, gastrointestinal stromal tumors, neuroendocrine tumors, lymphoma, and others. The adenocarcinomas segment held a significant share of the market in 2022 and is expected to register the highest CAGR in the stomach cancer market during 2022–2030.

Based on treatment, the stomach cancer market is categorized into targeted and immunotherapy drugs, chemotherapy and combination drugs, and others. In 2022, the chemotherapy and combination drugs segment held a significant share of the market. The targeted and immunotherapy drugs segment is expected to register the highest CAGR in the stomach cancer market during 2022–2030.

Based on route of administration, the stomach cancer market is segmented into oral, parenteral, and others. In 2022, the oral segment held a significant share of the market, and it is anticipated to record the fastest CAGR during 2022–2030.

Based on distribution channel, the stomach cancer market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held a significant share of the market in 2022 and is expected to register the highest CAGR during 2022–2030.

Regional Analysis:

The stomach cancer market is primarily divided into North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. In 2022, North America captured a significant share of the market. In 2022, the US held the largest share of the market in the region. The market growth in North America is attributed to the growing prevalence of gastric cancer, increasing adoption of targeted cancer therapy, and the accessibility of advanced technology in cancer research and treatment centers. The American Cancer Society anticipated that ~26,500 new cases of gastric cancer (15,930 in males and 10,570 in females) will be diagnosed in 2023. ~11,130 deaths (6,690 males and 4,440 females) will be due to gastric cancer. North America is well-developed in terms of the accessibility of advanced technological treatment options for reducing cancer, and businesses are working hard to compete with the well-known players in the region.

Moreover, the increasing company activities in conducting clinical trials for the development of effective drugs for patients with gastric cancer and increasing product launches and approvals are estimated to fuel the market growth in the region. In April 2021, the Food and Drug Administration (FDA) approved Bristol Myers Squibb's Opdivo, in combination with fluoropyrimidine and platinum-containing chemotherapy, for treating patients with advanced or metastatic gastric cancer and esophageal adenocarcinoma. Thus, such factors are likely to support the market growth in the region during the forecast period.

Stomach Cancer Market Regional Insights

The regional trends and factors influencing the Stomach Cancer Market throughout the forecast period have been thoroughly explained by the analysts at The Insight Partners. This section also discusses Stomach Cancer Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Stomach Cancer Market Report Scope

Stomach Cancer Market Players Density: Understanding Its Impact on Business Dynamics

The Stomach Cancer Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.

Major Companies operating in the Stomach Cancer Market are:

1. Bristol Myers Squibb Company
2. Novartis AG
3. Merck & Co., Inc.
4. Eli Lilly and Company
5. Biocon

Disclaimer: The companies listed above are not ranked in any particular order.

Industry Developments and Future Opportunities: 

Numerous initiatives taken by key players operating in the global stomach cancer market are listed below:

• In January 2021, AstraZeneca and Daiichi Sankyo Company received the approval of Enhertu from the US FDA for treating adult patients with advanced or metastatic HER2-positive gastric adenocarcinoma.

Competitive Landscape and Key Companies:

Bristol Myers Squibb Company; Novartis AG; Merck & Co., Inc.; Eli Lilly and Company; Biocon; Teva Pharmaceutical Industries Ltd; Celltrion Healthcare Co., Ltd; Samsung Bioepis; Pfizer Inc.; and Ipsen Pharma are among the prominent players in the stomach cancer market. These companies focus on introducing new high-tech products, advancements in existing products, and geographic expansions to meet the growing consumer demand worldwide.